With innovative lab technologies and a team of highly experienced pathologists, Bako Diagnostics is the podiatric medical community’s premier pathology services partner.
BakoDx services include laboratory evaluation of nail, skin, wound, nerve, soft tissue and bone of the lower extremity.
“Each specimen that arrives at our laboratory represents a real patient,” said Ted Hull, BakoDx CEO. “Because of that, we work diligently to exceed all expectations and deliver exceptionally detailed reports, services and therapeutic treatment recommendations to improve patient care and outcomes.”
BakoDx’s in-network services are available to more than 250 million covered lives, including all five national health plans and more than 200 additional insurance providers.
WHY IS DNA (PCR) TESTING FOR NAIL DYSTROPHY?
Because not all dystrophic nails are onychomycosis, clinical diagnosis alone can often be inaccurate. Bako’s proprietary onychodystrophy DNA (PCR) test optimizes cost and offers rapid results, to enable better patient care. The BakoDx onychodystrophy DNA test provides the causative agent of nail infection within 24-48 hours. This allows physicians to deliver fast, evidence-based results that target and treat the underlying infectious pathogens implicated in onychomycosis, including dermatophytes, saprophytes and/or yeast. In addition, the test detects the most common bacterial cause of nail infection — Pseudomonas aeruginosa, the causative agent of green nail syndrome.
By detecting and identifying the correct causative agent of disease, unnecessary expense to patients and payers are eliminated. Most national health insurance payers require genus/species identification for preauthorization of some anti-fungal prescriptions. The BakoDx onychodystrophy test is covered by Medicare and most healthcare insurance plans.
BETTER TOGETHER: DNA (PCR) + HISTOLOGY
BakoDx’s onychodystrophy test is designed to complement histopathology. Because only half of the onychodystrophy cases are onychomycosis, when clinicians include histopathology, their patients’ specimen is evaluated for non-infectious causes, including trauma, neoplastic processes, psoriasis and other inflammatory etiologies. Potential evaluations include PAS, GMS and FM stains.
“Fifty-percent of what we see is onychomycosis and 50 percent is something else, like psoriasis,” said Dr. Tracey Vlahovic, Associate Professor for Temple University Department of Podiatric Medicine and a BakoDx Medical Advisor Board Member. “You want to make sure that you’re dealing with onychomycosis and not another disease entity. You certainly don’t want to give an oral anti-fungal to someone who has nail psoriasis. And likewise, depending on what the results come back as, if it’s a mold, or an exotic dermatophyte, you want to make sure that you are choosing the correct drug for that bug.”
BakoDx pathologists provide the clinician with a comprehensive evaluation of nail unit dystrophy and the potential therapeutic recommendations to treat the underlying cause of the disease. Visit BakoDx.com or call 855-422-5628 to learn more.